Details of the Drug

General Information of Drug (ID: DM9UB0P)

Drug Name

Oxaprozin

Synonyms

Actirin; Alvo; Danoprox; Daypro; Dayrun; Deflam; Oxaprozina; Oxaprozine; Oxaprozinum; Voir; Xopane; Apotex brand of oxaprozin; CSC brand of oxaprozin; Pfizer brand of oxaprozin; Rhoxalpharma brand of oxaprozin; TRB brand of oxaprozin; Lyl)propenoic acid; NCI310839; O 9637; WY 21743; Apo-Oxaprozin; Daypro (TN); Duraprox (TN); Oxaprozina [INN-Spanish]; Oxaprozine [INN-French]; Oxaprozinum [INN-Latin]; Rhoxal-oxaprozin; WY-21743; WY-21,743; Oxaprozin (JP15/USAN/INN); Oxaprozin [USAN:BAN:INN:JAN]; Beta-(4,5-Diphenyloxazol-2-yl)propionic acid; 3-(4, 5-Diphenyl-2-oxazo; 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid; 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid; 4, 5-Diphenyl-2-oxazolepropionic acid; 4,5-Diphenyl-2-oxazolepropanoic acid; 4,5-Diphenyl-2-oxazolepropionic acid

Indication

Disease Entry	ICD 11	Status	REF
Osteoarthritis	FA00-FA05	Approved	[1]
Rheumatoid arthritis	FA20	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

293.3

Logarithm of the Partition Coefficient (xlogp)

4.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability: 98% of drug becomes completely available to its intended biological destination(s) [4]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 54.9 hours [5]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 88.6374 micromolar/kg/day [6]
Vd: The volume of distribution (Vd) of drug is 11-17 L []
Water Solubility: The ability of drug to dissolve in water is measured as 1.7 mg/mL [3]

Chemical Identifiers

Formula: C18H15NO3
IUPAC Name: 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid
Canonical SMILES: C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3
InChI: InChI=1S/C18H15NO3/c20-16(21)12-11-15-19-17(13-7-3-1-4-8-13)18(22-15)14-9-5-2-6-10-14/h1-10H,11-12H2,(H,20,21)
InChIKey: OFPXSFXSNFPTHF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4614
ChEBI ID: CHEBI:7822
CAS Number: 21256-18-8
DrugBank ID: DB00991
TTD ID: D0M9DC
INTEDE ID: DR1212
ACDINA ID: D00498

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase (COX)	TTK0943	PGH1_HUMAN ; PGH2_HUMAN	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 4A11 (CYP4A11)	OTPU5J0S	CP4AB_HUMAN	Gene/Protein Processing	[9]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Gene/Protein Processing	[10]
HLA class II histocompatibility antigen, DQ beta 1 chain (HLA-DQB1)	OTVVI3UI	DQB1_HUMAN	Gene/Protein Processing	[11]
Peroxisome proliferator-activated receptor gamma (PPARG)	OTHMARHO	PPARG_HUMAN	Gene/Protein Processing	[12]
Tumor necrosis factor receptor superfamily member 16 (NGFR)	OTPKSM49	TNR16_HUMAN	Gene/Protein Processing	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oxaprozin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Oxaprozin and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[13]
Glibenclamide	DM8JXPZ	Moderate	Increased risk of hypoglycemia by the combination of Oxaprozin and Glibenclamide.	Acute diabete complication [5A2Y]	[14]
Glipizide	DMZA5PQ	Moderate	Increased risk of hypoglycemia by the combination of Oxaprozin and Glipizide.	Acute diabete complication [5A2Y]	[14]
Inotersen	DMJ93CT	Major	Increased risk of bleeding by the combination of Oxaprozin and Inotersen.	Amyloidosis [5D00]	[15]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Oxaprozin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[16]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Cilostazol.	Arterial occlusive disease [BD40]	[17]
Budesonide	DMJIBAW	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Oxaprozin and Budesonide.	Asthma [CA23]	[18]
Ofloxacin	DM0VQN3	Moderate	Additive CNS stimulant effects by the combination of Oxaprozin and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[19]
Kanamycin	DM2DMPO	Moderate	Increased risk of nephrotoxicity by the combination of Oxaprozin and Kanamycin.	Bacterial infection [1A00-1C4Z]	[20]
Sparfloxacin	DMB4HCT	Moderate	Additive CNS stimulant effects by the combination of Oxaprozin and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[19]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Oxaprozin and Streptomycin.	Bacterial infection [1A00-1C4Z]	[20]
Gemifloxacin	DMHT34O	Moderate	Additive CNS depression effects by the combination of Oxaprozin and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[19]
Norfloxacin	DMIZ6W2	Moderate	Additive CNS stimulant effects by the combination of Oxaprozin and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[19]
ABT-492	DMJFD2I	Moderate	Additive CNS depression effects by the combination of Oxaprozin and ABT-492.	Bacterial infection [1A00-1C4Z]	[19]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of nephrotoxicity by the combination of Oxaprozin and Etidronic acid.	Bone paget disease [FB85]	[21]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Oxaprozin and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[22]
Iodipamide	DMXIQYS	Major	Increased risk of nephrotoxicity by the combination of Oxaprozin and Iodipamide.	Cholelithiasis [DC11]	[23]
Levomilnacipran	DMV26S8	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Levomilnacipran.	Chronic pain [MG30]	[24]
Regorafenib	DMHSY1I	Major	Increased risk of bleeding by the combination of Oxaprozin and Regorafenib.	Colorectal cancer [2B91]	[15]
Drospirenone	DM1A9W3	Moderate	Increased risk of hyperkalemia by the combination of Oxaprozin and Drospirenone.	Contraceptive management [QA21]	[25]
Ardeparin	DMYRX8B	Major	Increased risk of bleeding by the combination of Oxaprozin and Ardeparin.	Coronary thrombosis [BA43]	[26]
Danaparoid	DM6CLBN	Major	Increased risk of bleeding by the combination of Oxaprozin and Danaparoid.	Deep vein thrombosis [BD71]	[26]
Rivaroxaban	DMQMBZ1	Major	Increased risk of bleeding by the combination of Oxaprozin and Rivaroxaban.	Deep vein thrombosis [BD71]	[27]
Sertraline	DM0FB1J	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Sertraline.	Depression [6A70-6A7Z]	[24]
Vilazodone	DM4LECQ	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Vilazodone.	Depression [6A70-6A7Z]	[24]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Vortioxetine.	Depression [6A70-6A7Z]	[24]
Milnacipran	DMBFE74	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Milnacipran.	Depression [6A70-6A7Z]	[24]
Escitalopram	DMFK9HG	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Escitalopram.	Depression [6A70-6A7Z]	[24]
Desvenlafaxine	DMHD4PE	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Desvenlafaxine.	Depression [6A70-6A7Z]	[24]
Clomipramine	DMINRKW	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Clomipramine.	Depression [6A70-6A7Z]	[24]
Cannabidiol	DM0659E	Moderate	Increased risk of hepatotoxicity by the combination of Oxaprozin and Cannabidiol.	Epileptic encephalopathy [8A62]	[15]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Tazemetostat.	Follicular lymphoma [2A80]	[17]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Oxaprozin and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[15]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of hepatotoxicity by the combination of Oxaprozin and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[28]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Oxaprozin and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[29]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Oxaprozin and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[30]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Oxaprozin and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[31]
Trichlormethiazide	DMHAQCO	Moderate	Antagonize the effect of Oxaprozin when combined with Trichlormethiazide.	Hypertension [BA00-BA04]	[32]
Balsalazide	DM7I1T9	Moderate	Increased risk of nephrotoxicity by the combination of Oxaprozin and Balsalazide.	Indeterminate colitis [DD72]	[33]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[34]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Oxaprozin and Idelalisib.	Mature B-cell leukaemia [2A82]	[35]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Oxaprozin and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[36]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Oxaprozin and Ibrutinib.	Mature B-cell lymphoma [2A85]	[37]
Ponatinib	DMYGJQO	Major	Increased risk of bleeding by the combination of Oxaprozin and Ponatinib.	Mature B-cell lymphoma [2A85]	[38]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Oxaprozin and Exjade.	Mineral absorption/transport disorder [5C64]	[39]
Panobinostat	DM58WKG	Major	Increased risk of bleeding by the combination of Oxaprozin and Panobinostat.	Multiple myeloma [2A83]	[13]
Deflazacort	DMV0RNS	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Oxaprozin and Deflazacort.	Muscular dystrophy [8C70]	[18]
Dasatinib	DMJV2EK	Major	Increased risk of bleeding by the combination of Oxaprozin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[40]
Omacetaxine mepesuccinate	DMPU2WX	Major	Increased risk of bleeding by the combination of Oxaprozin and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[41]
Prasugrel	DM7MT6E	Major	Increased risk of bleeding by the combination of Oxaprozin and Prasugrel.	Myocardial infarction [BA41-BA43]	[15]
Vorapaxar	DMA16BR	Major	Increased risk of bleeding by the combination of Oxaprozin and Vorapaxar.	Myocardial infarction [BA41-BA43]	[42]
Sibutramine	DMFJTDI	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Sibutramine.	Obesity [5B80-5B81]	[24]
Dexfenfluramine	DMJ7YDS	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Dexfenfluramine.	Obesity [5B80-5B81]	[24]
Polythiazide	DMCH80F	Moderate	Antagonize the effect of Oxaprozin when combined with Polythiazide.	Oedema [MG29]	[32]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Oxaprozin and MK-4827.	Ovarian cancer [2C73]	[15]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Epoprostenol.	Pulmonary hypertension [BB01]	[43]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Iloprost.	Pulmonary hypertension [BB01]	[43]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Oxaprozin and Everolimus.	Renal cell carcinoma [2C90]	[44]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Oxaprozin and Temsirolimus.	Renal cell carcinoma [2C90]	[44]
Gatifloxacin	DMSL679	Moderate	Additive CNS stimulant effects by the combination of Oxaprozin and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[19]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Oxaprozin and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[15]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Oxaprozin and Pitolisant.	Somnolence [MG42]	[15]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Caplacizumab.	Thrombocytopenia [3B64]	[17]
Apixaban	DM89JLN	Major	Increased risk of bleeding by the combination of Oxaprozin and Apixaban.	Thrombosis [DB61-GB90]	[15]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Cangrelor.	Thrombosis [DB61-GB90]	[17]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Oxaprozin and Brilinta.	Thrombosis [DB61-GB90]	[15]
Cabozantinib	DMIYDT4	Major	Increased risk of bleeding by the combination of Oxaprozin and Cabozantinib.	Thyroid cancer [2D10]	[45]
Tolbutamide	DM02AWV	Moderate	Increased risk of hypoglycemia by the combination of Oxaprozin and Tolbutamide.	Type 2 diabetes mellitus [5A11]	[14]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Oxaprozin and Olsalazine.	Ulcerative colitis [DD71]	[33]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Oxaprozin and Plazomicin.	Urinary tract infection [GC08]	[20]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Oxaprozin and Betrixaban.	Venous thromboembolism [BD72]	[46]
-----------


⏷ Show the Full List of 71 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Quinoline yellow WS	E00309	24671	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Carmellose sodium	E00625	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Oxaprozin 600 mg tablet	600 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Oxaprozin FDA Label
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
8	Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. J Clin Pharmacol. 1997 Apr;37(4):267-78.
9	Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
10	A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
11	Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
12	Nonsteroidal anti-inflammatory drugs induce apoptosis in association with activation of peroxisome proliferator-activated receptor gamma in rheumatoid synovial cells. J Pharmacol Exp Ther. 2002 Jul;302(1):18-25. doi: 10.1124/jpet.302.1.18.
13	Cerner Multum, Inc. "Australian Product Information.".
14	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
15	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
16	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
17	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
18	Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
19	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
20	Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
21	Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
22	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
23	Wong GT, Lee EY, Irwin MG. Contrast induced nephropathy in vascular surgery.?Br J Anaesth. 2016;117 Suppl 2:ii63-ii73. [PMID: 27566809]
24	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
25	Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
26	Bang CJ, Riedel B, Talstad I, Berstad A "Interaction between heparin and acetylsalicylic acid on gastric mucosal and skin bleeding in humans." Scand J Gastroenterol 27 (1992): 489-94. [PMID: 1321488]
27	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
28	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
29	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
30	EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
31	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
32	Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
33	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
34	Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
35	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
36	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
37	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
38	Product Information. Iclusig (ponatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
39	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
40	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
41	Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
42	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
43	Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
44	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
45	Product Information. Cometriq (cabozantinib). Exelixis Inc, S San Francisco, CA.
46	Product Information. Bevyxxa (betrixaban). Portola Pharmaceuticals, South San Francisco, CA.